Abstract
Clinical and histological effects of Cromolyn (DSCG) were studied in 12 patients with inflammatory bowel disease (IFBD) (5 Crohn's and 7 UC). Patients had refractory disease for at least 1 year. Treatment varied from 6-18 months and was not associated with adverse effects. Granulated mast cells were estimated in the lamina propria of normal control specimens (22) and others with IFBD. Biopsies were classified as normal, healed or chronic active. Index of disease activity was recorded for each patient. Results were in mast cells/mm2: Normal-343; UC-323 and Crohn's-304. During DSCG treatment: in Crohn's disease 3 of 5 (60%) improved clinically and 2 had progressive disease. Those who improved showed a mean increase of 105 mast cells/mm2 (from 267 to 372). In UC, 6 of 7 improved clinically (85%). Four of these showed a mean increase of 148 mast cells/mm2 (from 239 to 387/mm2). Two who improved clinically but had no increase in mast cells had active histologic disease pre and post-treatment. Overall, those who responded best to drug both by clinical and histologic criteria showed an increase in mast cells. DSCG is of value in the therapy of IFBD, and its effects may be directly related to its action on mast cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
